GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
41.25
+0.42 (+1.03%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close40.83
Open40.91
Bid0.00 x 27000
Ask0.00 x 4000
Day's Range40.88 - 41.28
52 Week Range34.52 - 42.36
Volume1,872,883
Avg. Volume2,463,414
Market Cap106.036B
Beta0.66
PE Ratio (TTM)74.46
EPS (TTM)0.55
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield2.17 (5.29%)
Ex-Dividend Date2018-05-10
1y Target Est42.19
Trade prices are not sourced from all markets
  • Jeff Auxier Trims Keurig Dr Pepper, Twenty-First Century Fox Positions
    GuruFocus.comyesterday

    Jeff Auxier Trims Keurig Dr Pepper, Twenty-First Century Fox Positions

    Jeff Auxier ( Trades , Portfolio ), p resident and CEO of Auxier Asset Management, sold shares of the following stocks during the second quarter. Warning! GuruFocus has detected 2 Warning Sign with XPAR:GLE. The guru reduced his holding of Keurig Dr Pepper Inc. (KDP) by 61.48%.

  • Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication
    Zacksyesterday

    Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

    Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

  • A Performance Overview of Bausch’s Diversified Products Business
    Market Realistyesterday

    A Performance Overview of Bausch’s Diversified Products Business

    Bausch Health Companies’ (BHC) Diversified Products segment reported net revenue of $336 million in the second quarter compared to $461 million in the second quarter of 2017, a ~27% YoY (year-over-year) fall.

  • Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study
    Zacks2 days ago

    Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study

    Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.

  • Gauging Analysts’ Expectations for Novavax and Peers in August
    Market Realist2 days ago

    Gauging Analysts’ Expectations for Novavax and Peers in August

    Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing to market recombinant nanoparticle vaccines and adjuvants. Novavax makes use of its proprietary recombinant nanoparticle vaccine technology and saponin-based adjuvant technology to develop vaccine candidates that target different infectious diseases, such as the respiratory syncytial virus and influenza. Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation (or BMGF), which is the current source of its revenue.

  • Should Gilead Be Worried About This New Monthly HIV Medication?
    Motley Fool2 days ago

    Should Gilead Be Worried About This New Monthly HIV Medication?

    The devil is in the undisclosed details.

  • Long-acting injection a shot in the arm for GSK's HIV business
    Reuters3 days ago

    Long-acting injection a shot in the arm for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.

  • Reuters3 days ago

    Commodities slide pulls FTSE to three-and-a-half month closing low

    By Kit Rees and Helen Reid LONDON (Reuters) - Britain's top share index sank on Wednesday as emerging markets stress and a sharp selloff in commodities drove down stocks across Europe, with investors running ...

  • Long-acting injection a shot in the arm for GSK's HIV business
    Reuters3 days ago

    Long-acting injection a shot in the arm for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.

  • CNBC3 days ago

    Stocks making the biggest moves premarket: M, STZ, EGN, GSK, WMT & more

    Macy's M – The retailer earned an adjusted 70 cents per share for the second quarter, topping estimates, with revenue also beating forecasts. Comparable sales posted an unexpected rise of 0.5 percent, compared to forecasts of a 0.

  • Analysts’ Recommendations for GlaxoSmithKline Stock
    Market Realist3 days ago

    Analysts’ Recommendations for GlaxoSmithKline Stock

    This year, analysts expect GlaxoSmithKline’s (GSK) revenue to grow 0.4% YoY (year-over-year) to ~30.3 billion British pounds from ~30.2 billion pounds, and its income margin to narrow YoY to 17.9% from 18.1%. They expect it to report EPS of 110.75 pence.

  • The Wall Street Journal4 days ago

    [$$] European Corporate Roundup for Wednesday

    European Corporate Roundup for Wednesday Admiral Group 1H Interim Profit Rose on Motor-Unit Growth Admiral Group PLC said Wednesday that its first-half profit rose on growth in its core U.K. motor-insurance business, despite poor weather hurting its household unit.

  • Financial Times4 days ago

    [$$] GSK sees positive signs from trials of reduced HIV treatment

    GlaxoSmithKline’s HIV division has welcomed the results of a trial that could see the drug regime of patients cut from a daily dose of three drugs to a monthly injection of two. ViiV Healthcare hopes that developing the two-drug products will boost GSK’s share of the $20bn-a-year market for HIV treatment, addressing toxicity concerns among people living with HIV by reducing the number of medicines they need to take. In the case of the injectable version, ViiV wants to be able to free HIV patients from having to take daily treatment.

  • Reuters4 days ago

    Long-acting injection boosts hopes for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's ...

  • A Look at Novo Nordisk’s Human Insulin and Obesity Business
    Market Realist4 days ago

    A Look at Novo Nordisk’s Human Insulin and Obesity Business

    In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.

  • Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018
    Market Realist4 days ago

    Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018

    GlaxoSmithKline’s (GSK) Vaccines segment includes its influenza, meningitis, shingles, and established vaccines. The segment’s revenue grew 13% YoY (year-over-year) to ~1.3 billion British pounds in Q2 2018, as a result of 16% operating revenue growth and a 3% impact by foreign exchange. The chart below shows the segment’s revenue since the first quarter of 2017.

  • What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
    Market Realist4 days ago

    What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.

  • GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018
    Market Realist4 days ago

    GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.

  • Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
    Motley Fool4 days ago

    Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb

    Which stock wins in a matchup between these two big pharma companies?

  • The Wall Street Journal5 days ago

    [$$] Orchard Therapeutics Raises $150 Million After GlaxoSmithKline Deal

    Orchard Therapeutics has raised $150 million after bulking up its portfolio of gene therapies through an agreement with GlaxoSmithKline.

  • How GlaxoSmithKline’s Segments Have Performed
    Market Realist5 days ago

    How GlaxoSmithKline’s Segments Have Performed

    As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...

  • Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?
    Market Realist5 days ago

    Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?

    Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.

  • Analyzing GlaxoSmithKline’s Revenue Trends
    Market Realist5 days ago

    Analyzing GlaxoSmithKline’s Revenue Trends

    In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.

  • How GlaxoSmithKline’s Valuation Compares with Peers’
    Market Realist5 days ago

    How GlaxoSmithKline’s Valuation Compares with Peers’

    Global pharmaceutical company GlaxoSmithKline (GSK) is aiming for sustainable growth by focusing on its business beyond pharmaceuticals. The company, which reports its financial results in British pounds, beat analysts’ EPS and revenue estimates of ~26.1 pence and 7.2 billion pounds in Q2 2018, reporting EPS of 28.1 pence and revenue of 7.3 billion pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since the first quarter of 2017. 

  • Reuters5 days ago

    Orchard raises $150 million to expand after GSK gene therapy deal

    Anglo-American biotech company Orchard Therapeutics has raised a further $150 million (117.7 million pounds) to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million (109.8 million pounds). The new financing comes four months after its acquisition of a portfolio of GlaxoSmithKline (GSK.L) rare disease medicines, including the gene therapy Strimvelis for ADA severe combined immune deficiency (ADA-SCID), or "bubble baby" disease. Gene therapy is a hot area for drug research - highlighted by Novartis's (NOVN.S) $8.7 billion (6.8 billion pounds) acquisition of AveXis in April - but products sold to Orchard are viewed as too niche for GSK as it refocuses its drug research under CEO Emma Walmsley.